Gilead Sciences (GILD) Misses Q4 EPS by 83c; Offers 2022 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $0.69, $0.83 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.51 billion.

GUIDANCE:

Gilead Sciences sees FY2022 EPS of $6.20-$6.70, versus the consensus of $6.91. Gilead Sciences sees FY2022 revenue of $23.8-24.3 billion, versus the consensus of $24.39 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Accenture downgraded by TD Cowen on AI concerns